Skip to main content

Table 5 Comparison of the main adverse events and antithrombotic therapy according to the number of CMBs

From: The safety of antithrombotic therapy in patients with cerebral microbleeds and cardiogenic cerebral embolism due to nonvalvular atrial fibrillation

 

Number of CMBs

χ2

P value

≤5 n = 46

6–9 n = 24

≥10 n = 40

Antithrombotic therapy

 Anticoagulant therapy (%)

18 (39.1)

8 (33.3)

28 (70.0)

11.208

0.004

 Antiplatelet therapy (%)

28 (60.9)

16 (66.7)

12 (30.0)

  

CH events (%)

6 (13.0)

2 (8.3)

10 (25.0)

3.681

0.159

All-cause death (%)

8 (17.4)

2 (8.3)

4 (10.0)

1.586

0.453